srch

Founded in 2015, Boston Pharmaceuticals is an early phase drug development company dedicated to rapidly transforming the right molecules into the best medicines™ for patients. We are a team of veteran drug developers who are passionate about transforming the right molecules into the best medicines. We attribute our success in our pipeline to ...

WHAT WE DO. We acquire innovative molecules from pharmaceutical and biotechnology companies and transform them into differentiated therapeutics that improve patients’ lives. We bring drug development programs into our pipeline as early as candidate selection and advance candidates to an appropriate value inflection point.

02.01.2022 · About Servier Pharmaceuticals:<br><br>We’re an organization, committed to modeling diversity, equity, and inclusion for the entire industry, and to maintaining an inclusive environment with equitable treatment for all. We are interested in growing our team with passionate, committed, and innovative individuals. We encourage all to apply to our open roles …

We have built a pipeline that spans multiple therapeutic areas, modalities, and technologies to address unmet medical needs. To expand and view complete pipeline, click here. Autoimmune 2 Programs. Follow the data to improve patient outcomes. Learn More. Click to Expand. BOS161721 (avizakimab) IL-21 Mab.

Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, Novartis ...

WHO WE ARE. We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of pharmaceutical industry experience. LEADERSHIP.

Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 ... while maintaining pipeline optionality for the future.

01.09.2020 · Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21. In many NASH patients, there is a deficiency in fibroblast growth factor 21 (FGF21), which can lead to the development of steatosis, inflammation, hepatocyte damage and fibrosis in the liver.

We have built a pipeline that spans multiple therapeutic areas, modalities, and technologies to address unmet medical needs.

Our Pipeline Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases. Our Licensed Small Molecule Oncology Programs Our Licensed Small Molecule Autoimmune & Dermatology Programs Our CNS Program Available for Licensing

26.04.2021 · Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates.

04.09.2021 · Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have...

Boston Pharmaceuticals will assume full responsibility from GSK to ... of our strategy to assemble a diverse pipeline of clinical candidates ...

Oct 03, 2018 · Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK. Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals. From GlaxoSmithKline, the Cambridge, Mass.-based company in-licensed five early development programs. The portfolio includes two compounds ready for Phase ...

We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in ...

Pipeline. Deals. Financings. Articles. Boston Pharmaceuticals Inc. Headquarters: Cambridge, MA. Website: http://www.bostonpharmaceut.

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for …

Boston Pharmaceuticals | 3513 followers on LinkedIn. ... multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Pipeline Prospector delivers free access to a database of Oncology drugs under clinical trials which made headlines done by Boston Pharmaceuticals.

We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline. Boston Pharmaceuticals | 3,507 ...

WHO WE ARE. We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of pharmaceutical industry experience. LEADERSHIP.

Turning the right molecules into the best medicines™. We attribute our success in our pipeline to the exceptional people working at Boston Pharmaceuticals. We embrace the development of our employees and seek passionate, science-driven candidates with an intellectual curiosity for more.

We have built a pipeline that spans multiple therapeutic areas, modalities, and technologies to address unmet medical needs. ... Boston Pharmaceuticals 55 Cambridge ...

Boston Pharmaceuticals and GlaxoSmithKline have entered into a three-year ... assets while maintaining pipeline optionality for the future.

Complementing the Boston Pharmaceuticals team is a network of best-in-class development partners strategically integrated into our programs. This blended model allows us to flexibly scale across programs, return more value to our partners and ultimately bring the best medicines to patients.